Bazedoxifene: literature data and clinical evidence

Area of Science:

• Endocrinology
• Bone Metabolism
• Pharmacology

Background:

• Postmenopausal osteoporosis remains a significant health concern, with unresolved challenges in prevention and treatment.
• Despite available therapies, a substantial number of patients remain untreated or undertreated, highlighting an unmet medical need.
• Decreased use of Hormone Therapy (HT) post-Women's Health Initiative (WHI) has potentially increased osteoporosis risk.

Purpose of the Study:

• To determine the role of Bazedoxifene acetate (BZA), a selective estrogen receptor modulator (SERM), in managing postmenopausal osteoporosis.
• To evaluate BZA within the landscape of existing therapeutic options for osteoporosis prevention and treatment.
• To address the ongoing need for effective and safe treatments for osteoporosis.

Main Methods:

• Convening a Multidisciplinary National Panel of Experts in Menopause and Postmenopausal Osteoporosis management.
• Reviewing current therapeutic options and unmet needs in osteoporosis care.
• Assessing the potential of BZA as a treatment option.

Main Results:

• The panel identified BZA as a valuable therapeutic option for postmenopausal osteoporosis.
• Emphasis was placed on recognizing osteopenia as a fracture risk factor.
• The importance of fracture risk assessment algorithms (e.g., FRAX®, deFRA®) integrating Bone Mineral Density (BMD) and clinical factors was highlighted.

Conclusions:

• Bazedoxifene acetate (BZA) offers a promising therapeutic strategy for postmenopausal osteoporosis.
• Increased clinical awareness and utilization of fracture risk assessment tools are essential for timely intervention.
• Continued development of effective treatments is crucial to mitigate the impact of osteoporosis and reduce fracture-related morbidity and healthcare costs.